Cytokinetics, Inc. (CYTK) Posts Q2 Loss of 23c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Cytokinetics (CYTK) Valuation Remains Attractive Following Q2 Results - Roth
July 31, 2014 2:17 PM EDTRoth Capital reaffirms its Buy rating and $13 price target on Cytokinetics (Nasdaq: CYTK) following the company's Q2 report.
Ahead of the bell, Cytokinetics posted Q2 loss of $0.23 per share with revenue of $7.8 million, versus consensus estimates calling for a loss of $0.32 per share and revs of $7.0 million. Roth was looking for a loss of $0.38 per share and revenue of $4.0 million.
Roth analyst Joseph Pantginis... More
